SC10914

DRUG3 trials

Sponsors

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Conditions

Advanced Ovarian CancerAdvanced Solid TumorsBRCA 1 Gene MutationBRCA 2 Gene MutationBreast Cancer Metastatic

Phase 1

A Study of SC10914 in Patients With Advanced Solid Tumors

Jiangxi Qingfeng Pharmaceutical Co. Ltd.Advanced Solid Tumors

Start: 2016-10-31End: 2018-05-31Target: 72Updated: 2017-12-06

Phase 2

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

Jiangxi Qingfeng Pharmaceutical Co. Ltd.BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Cancer Metastatic

Start: 2020-08-12End: 2022-08-30Target: 78Updated: 2020-09-21

Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer

Jiangxi Qingfeng Pharmaceutical Co. Ltd.Advanced Ovarian Cancer

Start: 2020-12-15End: 2022-12-31Target: 104Updated: 2021-05-12

Related Papers

Phase I study to assess the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary efficacy of SC10914 in patients with advanced solid tumors.

Journal of Clinical Oncology2020-05-20